

EDITORIAL

Reperfusion in Acute Myocardial Infarction: How is the Future Shaping up?

Demosthenes Katritsis, MD, PhD, FACC, FESC

Department of Cardiology, Athens Euroclinic, Athens, Greece, & St Thomas' Hospital, London, England

ABSTRACT

Current evidence from several clinical trials indicates that primary angioplasty in patients with acute myocardial infarction (AMI) appears superior reperfusion therapy to immediate thrombolysis, even when transfer to an angioplasty center is necessary. Thus, organization of ambulance systems and adequate angioplasty facilities appears to be the key issue in providing the most effective contemporary reperfusion therapy for AMI. Furthermore, on-site primary coronary angioplasty in high-risk AMI patients at hospitals with no cardiac surgery on-site is nowadays considered safe, effective, and faster than angioplasty after transfer to a surgical facility.

Randomized trials have demonstrated the superiority of primary angioplasty with stent implantation over balloon angioplasty alone in the treatment of AMI, including patients with diabetes. Stent use has been associated with significant decreases in length of stay, major adverse cardiovascular events, and in-hospital mortality. Finally, because of the risk of stent thrombosis, the issue of whether drug-eluting stents are safe or even more beneficial than bare-metal stents in patients with AMI, as in other non-AMI patient groups, remains uncertain, although preliminary data seem to favour the use of drug-eluting stents.

KEY WORDS: *acute myocardial infarction, reperfusion, thrombolysis, primary angioplasty, coronary stents, antithrombotic agents*

INTRODUCTION

Acute myocardial infarction (AMI) has been associated with thrombotic occlusion of a coronary artery as early as in 1793 when an autopsy was performed on Sir James Hunter, a famous surgeon who died suddenly following a violent argument with hospital administrators in London.¹ The term “acute coronary thrombosis” was well established in medical literature and its connotation was reaffirmed following the seminal study of DeWood et al in 1980.² Thrombolytic agents were discovered in the 1950s and, following long debates about their clinical benefits,³ they entered clinical routine in 1986.⁴

However, it is now evident that although fresh thrombus represents the major pathological finding in acutely occluded coronary arteries, it is found in less than 70% of the cases.⁵⁻⁷ This is in keeping with the current success rates of thrombolytic trials that, even with the use of aggressive protocols, result in restoration of normal coronary flow (TIMI 3) in only 60 to 70% of the cases.⁸ It seems that a considerable proportion of AMI might be due to spontaneous dissection and/or severe intramural

ABBREVIATIONS

AMI = acute myocardial infarction
PTCA = percutaneous transluminal
coronary angioplasty

Correspondence to:

Demosthenes Katritsis, MD
Director of Cardiology
Euroclinic Hospital
Athens, Greece
E-mail: dkatritsis@euroclinic.gr

hemorrhage and extensive plaque rupture, in the context of preexisting atheromatosis. We know now that although soft, noncritical lesions are more prone to rupture and consequent acute thrombotic occlusion, rapid stenosis progression is not uncommon and complex stenoses are at risk more than smooth lesions to evolve into coronary occlusions.⁹ Resolution of any overlying thrombus by thrombolytic agents in this respect is unlikely to restore adequate antegrade flow in the coronary artery. Mechanical reperfusion, therefore, appears to be necessary in at least a proportion of patients with AMI and these patients cannot be identified in advance.

Furthermore, the incidence of intracranial hemorrhage following thrombolysis is estimated between 0.26 to 2.17% depending on preexisting risk factors.¹⁰ Thus, certain patient groups such as the elderly (>65 years), women, hypertensive patients and diabetics are at an increased risk of intracranial hemorrhage when subjected to thrombolysis. It has been shown that over 95% of patients presenting with AMI are acceptable candidates for primary angioplasty (PTCA), whereas up to 1/3 of cases are considered to have contraindications to thrombolysis.¹¹ Several patients are therefore being denied the benefits of revascularization in this respect and the possibility of direct revascularization seems to be a reasonable alternative.

PRIMARY PTCA VS THROMBOLYSIS

Since the first reported cases of primary angioplasty in 1983,¹² several thousands of patients have been enrolled in randomised trials comparing the interventional approach with thrombolysis. It is now clear that primary angioplasty performed in experienced centers offers higher patency rates of the infarcted vessel (85-90% at 90 minutes), decreased cost and length of hospital stay, lower stroke and recurrent infarction rates and lower 30-day and 6-month mortality as compared to thrombolytic therapy.¹³⁻¹⁸ In an early meta-analysis of 10 trials, primary angioplasty achieved a 35% decrease in mortality compared with thrombolytic therapy alone.¹⁹ Mechanical recanalization avoids the interstitial edema, contraction band necrosis and microvascular hemorrhage seen with thrombolysis.⁸ Early patency of the occluded artery is higher with decreased reocclusion rate and collateral flow to non-infarct-related myocardium is probably increased, thus allowing better healing of the infarcted area and less ventricular dilatation.¹⁸⁻²⁰ All these may well translate into an improved short-term outcome as well as long-term survival. WC Robert's admonition, therefore, "when I have an acute myocardial infarction take me to the hospital that has a cardiac catheterization laboratory and open cardiac surgical facilities" stated >20 years ago,²⁰ seems to be absolutely justified nowadays and if anything is to be argued this is only the need for surgical support.

PREREQUISITES FOR INTERVENTION

While thrombolysis is a relatively simple therapeutic procedure available even in primary care settings, PTCA requires the availability of institutions with cardiac catheterization facilities. Timely admission of the patient to such a unit is not always possible and the time to treatment with primary PTCA, as with thrombolytic therapy, is a critical determinant of mortality.^{21,22} In the GUSTO IIb trial the 30-day mortality rate of patients who underwent balloon inflation within 60 minutes after study enrolment was 1.0%, but beyond 90 minutes after enrolment, 6.4%.²³ It is now accepted that, although either fibrinolysis or PTCA can be considered within the first 12 hours from the onset of symptoms, the time interval for the implementation of primary PTCA should not exceed 2 hours after the diagnosis of AMI.²⁴

Primary PTCA also requires skilled operators performing at least 75 procedures per year.^{25,26} In busy centers absolute case volumes may not be as important but institutional experience, in general, influences complication rates and procedural outcomes.^{27,28} The issue of cardiac surgical back-up is currently under investigation. Although the ACC/AHA guidelines recommend standby facilities, evidence is accumulating that surgical coverage may not be necessary.²⁹⁻³¹

ANGIOPLASTY DEVICES AND ADJUNCTIVE PHARMACOTHERAPY

Aspirin and heparin (unfractionated or low molecular weight) should be given to all patients undergoing primary PTCA. A thienopyridine, such as clopidogrel, which appears to have a favourable safety profile should also be used regardless of the use of stents.³² These agents are also superior to anticoagulation with fewer cardiac events and less bleeding complications.³³

Several randomised trials have reported on the impact of stent use in primary PTCA.³⁴⁻⁴¹ There has been a tendency towards lower mortality with stenting, although not confirmed by all studies, and a significant reduction in the incidence of the subsequent target vessel revascularization (almost three-fold) with stenting. In one of the larger of the trials (PAMI-STENT)³⁷ there was also a slightly lower rate of TIMI 3 flow with stenting, thus raising the possibility of distal embolization of thrombus protruding through the stent struts at the time of deployment. Direct stenting without predilation has been reported to result in reduced microvascular injury and improved ST-segment resolution.⁴² The concomitant use of antiplatelet agents such as IIb/IIIa receptor blockers seems to reduce the incidence of this complication and several trials have addressed this issue.^{43-46,91} Results have shown better TIMI flows and reduced major adverse cardiac events at 6 months with the use of these agents, although restenosis rates were unaffected. Improvement of peak flow velocity and regional wall motion in the infarct area have been demonstrated with the use of IIb/IIIa following primary stenting,^{47,91} and these find-

ings did translate into a lower cumulative incidence of death, reinfarction, or stroke at 6 months as compared with thrombolysis alone.⁴³ The ADMIRAL trial⁴⁵ showed that initiation of abciximab before stenting resulted in improved TIMI flow immediately after the procedure and at 6 months. At 6-month follow-up, death rates were not different among groups but stents with IIB/IIIa inhibitors offered the lowest ischemic target revascularization rate. The CADILLAC study⁴⁶ randomized 2082 patients with AMI to undergo PTCA alone, PTCA plus abciximab, stenting alone, or stenting plus abciximab. At six months, the primary end point - a composite of death, reinfarction, stroke, and revascularization of the target vessel - had occurred in 20% of patients after PTCA, 16.5% after PTCA plus abciximab, 11.5% after stenting, and 10.2% after stenting plus abciximab ($P < 0.001$). However, there were no significant differences among the groups in the rates of death, stroke, or reinfarction; the difference in the incidence of the primary end point was due entirely to differences in the rates of target-vessel revascularization (ranging from 15.7% after PTCA to 5.2% after stenting plus abciximab). The rate of angiographically established restenosis was 40.8% after PTCA and 22.2% after stenting ($P < 0.001$), and the respective rates of reocclusion of the infarcted-related artery were 11.3% and 5.7% ($P = 0.01$), both independent of abciximab use. A recent meta-analysis also confirmed that primary stenting is superior to balloon angioplasty in reducing target vessel revascularization within the next year following AMI, although reinfarction or mortality rates were not affected.⁹⁰

Several mechanical strategies have also been evaluated in an effort to prevent microembolization and enhance myocardial perfusion. They include extraction atherectomy,⁴⁸ rheolytic atherectomy with the Angiojet device,⁴⁹ ultrasound thrombolysis,⁵⁰ thrombectomy with the X-sizer catheter,⁵¹ and filter protection with the Guardwire and the Filterwire.^{52,53}

However, the administration of antiplatelet agents or mechanical filters may not be enough to prevent distal embolization.⁵⁴ Even the achievement of TIMI 3 flow does not necessarily imply optimal myocardial perfusion.^{55,56} Distal embolization with capillary plugging and microcirculatory injury and dysfunction may be caused by the AMI process.^{56,57} Nevertheless, a recent meta-analysis of 21 randomized trials conducted with adjunctive mechanical devices to prevent distal embolization in 3721 patients with AMI, indicated that the use of adjunctive mechanical devices to prevent distal embolization is associated with better myocardial perfusion and less distal embolization, but without an apparent improvement in survival.⁵⁸

COST

Several analyses have found primary PTCA not to be more expensive than the conservative strategy using thrombolysis.⁵⁹⁻⁶¹ Actually primary angioplasty may reduce costs by offering lower readmission rates and shorter hospital stay.⁶²

SPECIFIC CLINICAL SETTINGS

Elderly patients, especially >75 years old, have an increased mortality after AMI and thrombolytic therapy may be of limited value in this setting.^{63,64} For patients 65 to 75 years old, thrombolytic therapy has been associated with a survival benefit, whereas among patients aged 76 to 86 years, it has been actually associated with a survival disadvantage.⁴⁷ Primary PTCA appears to have a particular advantage over thrombolysis for the management of AMI in the elderly and this has been a consistent finding in the initial primary angioplasty trials. Nevertheless, elderly patients undergoing primary revascularization have a higher complication and mortality rate than their younger counterparts.^{65,66}

Diabetics also appear to have a considerably better outcome with intervention rather than thrombolysis.^{8,28} Other situations in which thrombolysis is relatively less effective is congestive heart failure⁶⁷ and occlusion of saphenous bypass grafts.⁶⁸ Primary PTCA may also be beneficial in these patient cohorts⁶⁹ although graft angioplasty is associated with relatively higher adverse event rates.⁷⁰

The leading cause of death in patients hospitalized for AMI is cardiogenic shock and mortality rates ranges between 60 to 90% without treatment. The impact of thrombolysis in this respect is doubtful⁴ and mortality still exceeds 65%. Successful primary PTCA has been reported to reduce mortality rates to 30%.⁶⁷ According to the SHOCK randomized trial,⁶⁹ in patients with cardiogenic shock, emergency revascularization did not significantly reduce overall mortality at 30 days. This was also the case in the small, prematurely stopped SMASH trial.⁷¹ However, after 6 months there was a significant survival benefit in the SHOCK patients undergoing revascularization.⁶⁹ Prospective registries also suggest that early revascularization should be strongly considered for patients with acute myocardial infarction complicated by cardiogenic shock.⁷²

THE FUTURE: FACILITATED ANGIOPLASTY

Although the majority of patients subjected to thrombolysis are found to have a significant residual stenosis,⁷³ routine empirical use of PTCA following thrombolysis has not been found beneficial in early trials; actually there was a trend towards increased mortality following intervention in this setting.⁷⁴⁻⁷⁷ Recent data, however, from contemporary trials in the era of stents and IIB/IIIa antagonists, suggest a probable benefit of rescue PTCA in several distinct scenarios and that the pivotal mid-1980s studies suggesting no benefit or harm for PTCA after fibrinolytic therapy may no longer be relevant.^{78-80,93} This is particularly true for cases of failed thrombolysis. The RESCUE trial investigating the impact of angioplasty in patients with anterior AMI and angiographically demonstrated coronary occlusion reported a reduction in the composite end point of death or congestive heart failure at 30 days post-PTCA.⁷⁸ PTCA after failed fibrinolysis (TIMI 0 to 1 flow) appears to significantly reduce early severe heart

failure (3.8% vs 11.7%) and improve survival over 1 year in patients with moderate to large AMI (92% vs 87%), and possibly reduce early repeat AMI (4.3% vs 11.3%). Similar trends were reported in other trials.⁸¹⁻⁸³

More importantly, mechanical reperfusion in AMI has been found to result in better flow and outcome when performed on open than occluded arteries. The combination of low dose thrombolysis with subsequent angioplasty has been addressed by the PACT trial.⁸⁴ In this study, AMI patients subjected to rescue PTCA within one hour following half-dose t-PA (50 mg bolus) did not display higher rates of stroke or bleeding complications as compared to those treated with PTCA without previous thrombolysis. Left ventricular function, however, was significantly better in patients achieving TIMI 3 flow by the time of angiography or when produced by angioplasty. Long-term follow-up studies have also indicated that when reperfusion occurs before primary angioplasty, outcomes are better with improved procedural outcomes, smaller infarct size, better preservation of left ventricular function, and reduced mortality.⁸⁵ This has encouraged new strategies to establish reperfusion before primary angioplasty with platelet inhibitors and/or low-dose thrombolytic drugs. A combination of half dose thrombolysis with IIb/IIIa inhibitors in the GUSTO V trial⁸⁶ did not demonstrate increased rates of intracranial hemorrhage or disabling stroke as compared with thrombolysis alone. There is evidence, however, that this combination might reduce angiographically evident thrombus in AMI.⁹¹ The SPEED trial⁸⁷ studied 323 patients who underwent angioplasty with planned initial angiography 63 min following thrombolysis or half dose reteplase combined with IIb/IIIa inhibitors. Early angioplasty patients had fewer ischemic events and bleeding complications than did patients not undergoing early angioplasty. Patients receiving abciximab with reduced-dose reteplase showed an 86% incidence of TIMI grade 3 flow at approximately 90 min and a trend toward improved outcomes. The standard definition of TIMI flow grade 3 was used in this trial, however, instead of the "3 heart beat definition" for dye to traverse the artery that was adopted in other interventional trials.⁸⁹ Should the same criteria have been used by the SPEED investigators, an approximately 96% TIMI 3 rate would have been expected.⁸⁷ A retrospective analysis of the TIMI 14 data, also demonstrated greater ST-segment resolution following combination of low dose thrombolysis, IIb/IIIa antagonist and mechanical reperfusion, as compared to full-dose thrombolysis alone.^{92,93} Thus, both rescue angioplasty (artery closed before the procedure) and adjunctive angioplasty (artery open before the procedure) are beneficial in the setting of AMI.

This approach of facilitated angioplasty in order to reduce the time delay inherent with mechanical reperfusion is promising and is being currently studied in randomized trials. It is theoretically at least compatible with the "open vasculature" hypothesis which argues for the achievement of early flow,

full microvascular flow, full epicardial flow, and sustained flow.⁸⁹ It remains to be seen whether the higher efficacy can be combined with lower intracranial hemorrhage rates than those seen with ordinary thrombolysis. Recently, the CAPITAL AMI study showed that in patients presenting with high-risk STEMI, tenecteplase plus immediate angioplasty reduced the risk of recurrent ischemic events compared with tenecteplase alone and was not associated with an increase in major bleeding complications.⁹⁴

FINAL PERSPECTIVE

It is now abundantly clear that primary angioplasty in patients with AMI remains superior to immediate thrombolysis, even when transfer to an angioplasty center is necessary.⁹⁵ Organization of ambulance systems and adequate angioplasty facilities appear to be the key issues in providing the most effective reperfusion therapy for AMI. Furthermore, on-site primary angioplasty in high-risk AMI patients at hospitals with no cardiac surgery on-site is nowadays considered safe, effective, and faster than angioplasty after transfer to a surgical facility; on-site angioplasty and transfer groups have reported to have similar 30-day outcomes and more rapid reperfusion.⁹⁶

Randomized trials have demonstrated the superiority of primary angioplasty with stent implantation over balloon angioplasty alone in the treatment of AMI.^{97,98} Stent use has been associated with significant decreases in length of stay, major adverse cardiovascular events, and in-hospital mortality.⁹⁵ Diabetics with AMI also benefit from this strategy with stent implantation,⁹⁹ which significantly reduces restenosis and enhances survival free from target vessel revascularization, independent of IIb/IIIa use; however, survival remains reduced compared with survival in nondiabetic patients regardless of reperfusion modality. Finally, because of the risk of stent thrombosis, the issue of whether drug-eluting stents are safe or even more beneficial than bare-metal stents in patients with AMI, as in other non-AMI patient groups, remains uncertain. Preliminary studies of use of drug-eluting stents comparing their results with use of bare-metal stents, indicate lower AMI and death rates in mid-term follow-up with drug-eluting stents.¹⁰⁰ Further studies are needed to clarify this important issue.

REFERENCES

1. O'Neill WW. Coronary thrombosis during acute myocardial infarction: Roberts was right. *Am J Cardiol* 1998; 82:896-897.
2. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. *N Engl J Med* 1980; 303:897-902.
3. Braunwald E. The aggressive treatment of acute myocardial infarction. *Circulation* 1985; 71:1087-1092.
4. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto

- Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. *Lancet* 1986; 1:397-402.
5. Roberts WC, Buja LM. The frequency and significance of coronary arterial thrombi and other observations in fatal acute myocardial infarction. A study of 107 necropsy patients. *Am J Med* 1972; 52:425-443.
 6. DeWood MA, Spores J, Hensley GR, et al. Coronary arteriographic findings in acute transmural myocardial infarction. *Circulation* 1983; 68(suppl I):I39-49.
 7. Murakami T, Mizuno S, Takahashi Y, et al. Intracoronary aspiration thrombectomy for acute myocardial infarction. *Am J Cardiol* 1998; 82:839-844.
 8. Antman EM, Braunwald E. Acute Myocardial Infarction. In: Braunwald E, Zipes DP, Libby P (eds): Heart Disease, 1114-1218, Saunders 2001.
 9. Kaski JC, Chen L, Chester M, Katritsis D. Rapid progression of coronary artery stenoses assessed by quantitative coronary angiography. *Circulation* 1995; 92:2058-2065.
 10. Simoons ML, Maggioni AP, Knatterud G, et al. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. *Lancet* 1993; 342:1523-8.
 11. O'Keefe JH, Bailey WL, Rutherford BD. Primary angioplasty for acute myocardial infarction in 1,000 consecutive patients: results in an unselected population and high-risk subgroups. *Am J Cardiol* 1993; 72:107G-115G.
 12. Hartzler GO, Rutherford BD, McConahay DR, et al. Percutaneous transluminal coronary angioplasty with and without thrombolytic therapy for treatment of acute myocardial infarction. *Am Heart J* 1983; 106:965-73.
 13. Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. *N Engl J Med* 1993; 328:726-8.
 14. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. *N Engl J Med* 1993; 328:673-9.
 15. Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspirger MR, Gersh BJ. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups. *N Engl J Med* 1993; 328:685-691.
 16. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. *N Engl J Med* 1997 Jun 5; 336:1621-1628.
 17. Nunn CM, O'Neill WW, Rothbaum D, et al. Long-term outcome after primary angioplasty: report from the primary angioplasty in myocardial infarction (PAMI-I) trial. *J Am Coll Cardiol* 1999; 33:640-646.
 18. Zijlstra F, Hoorntje JC, de Boer MJ, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. *N Engl J Med* 1999; 341:1413-1419.
 19. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. *JAMA* 1997; 278:2093-2098.
 20. Roberts WC. When I have an acute myocardial infarction take me to the hospital that has a cardiac catheterization laboratory and open cardiac surgical facilities. *Am J Cardiol* 1984; 53:1410.
 21. Liem AL, van't Hof AW, Hoorntje JC, de Boer MJ, Suryapranata H, Zijlstra F. Influence of treatment delay on infarct size and clinical outcome in patients with acute myocardial infarction treated with primary angioplasty. *J Am Coll Cardiol* 1998; 32:629-633.
 22. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. *JAMA* 2000 Jun 14; 283(22):2941-2947.
 23. Berger PB, Ellis SG, Holmes DR Jr, et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. *Circulation* 1999; 100:14-20.
 24. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). *J Am Coll Cardiol* 1999; 34:890-911.
 25. Kastrati A, Neumann FJ, Schomig A. Operator volume and outcome of patients undergoing coronary stent placement. *J Am Coll Cardiol* 1998; 32:970-976.
 26. Malenka DJ, McGrath PD, Wennberg DE, et al. The relationship between operator volume and outcomes after percutaneous coronary interventions in high volume hospitals in 1994-1996: the northern New England experience. Northern New England Cardiovascular Disease Study Group. *J Am Coll Cardiol* 1999; 34:1471-1480.
 27. Ellis SG, Weintraub W, Holmes DR. Relation of operator volume and experience to procedural outcome of percutaneous coronary revascularization at hospitals with high interventional volumes. *Circulation* 1997; 96:2479-2484.
 28. Degeare VS, Dargas G, Stone GW, Grines CL. Interventional procedures in acute myocardial infarction. *Am Heart J* 2001; 141:15-24.
 29. Wharton TP Jr, McNamara NS, Fedele FA, Jacobs MI, Gladstone AR, Funk EJ. Primary angioplasty for the treatment of acute myocardial infarction: experience at two community hospitals without cardiac surgery. *J Am Coll Cardiol* 1999; 33:1257-1265.
 30. Wharton TP, Johnston JD, Turco MA, et al. Primary angioplasty for acute myocardial infarction with no surgery on site: outcomes, core angiographic analysis and six-month follow-up

- in the 500 patient prespective PAMI-No SOS registry. *J Am Coll Cardiol* 1999; 33(A Suppl):352A.
31. Angelini P. Guidelines for surgical standby for coronary angioplasty: should they be changed? *J Am Coll Cardiol* 1999; 33:1266-1268.
 32. Mehta SR, Yusuf S, Peters RJ, et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. *Lancet* 2001; 358:527-533.
 33. Schuhlen H, Kastrati A, Pache J, Dirschinger J, Schomig A. Sustained benefit over four years from an initial combined antiplatelet regimen after coronary stent placement in the ISAR trial. Intracoronary Stenting and Antithrombotic Regimen. *Am J Cardiol* 2001; 87:397-400
 34. Antoniucci D, Valenti R, Moschi G, et al. Cost-effective analysis of primary infarct-artery stenting versus optimal primary angioplasty (the Florence Randomized Elective Stenting in Acute Coronary Occlusions [FRESCO] trial). *Am J Cardiol* 2000; 85:1247-1249.
 35. Suryapranata H, Ottervanger JP, Nibbering E, et al. Long term outcome and cost-effectiveness of stenting versus balloon angioplasty for acute myocardial infarction. *Heart* 2001; 85:667-671.
 36. Rodriguez A, Bernardi V, Fernandez M, et al. In-hospital and late results of coronary stents versus conventional balloon angioplasty in acute myocardial infarction (GRAMI trial). Gianturco-Roubin in Acute Myocardial Infarction. *Am J Cardiol* 1998; 81:1286-1291.
 37. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. *N Engl J Med* 1999 Dec 23; 341(26):1949-1956.
 38. Saito S, Hosokawa G, Tanaka S, Nakamura S. Primary stent implantation is superior to balloon angioplasty in acute myocardial infarction: final results of the primary angioplasty versus stent implantation in acute myocardial infarction (PASTA) trial. PASTA Trial Investigators. *Catheter Cardiovasc Interv* 1999; 48:262-268.
 39. Escobar J, Guarda E, Marchant E, Fajuri A, Martinez A, Pichard A. Relation of stenting to decreased coronary blood flow during primary angioplasty in acute myocardial infarction. *Am J Cardiol* 2001; 88:1410-2, A6
 40. Le May MR, Labinaz M, Davies RF, et al. Stenting versus thrombolysis in acute myocardial infarction trial (STAT). *J Am Coll Cardiol* 2001; 37:985-991.
 41. Maillard L, Hamon M, Khalife K, et al. A comparison of systematic stenting and conventional balloon angioplasty during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. STENTIM-2 Investigators. *J Am Coll Cardiol* 2000; 35:1729-1736.
 42. Loubeyre C, Morice MC, Lefevre T, Piechaud JF, Louvard Y, Dumas P. A randomized comparison of direct stenting with conventional stent implantation in selected patients with acute myocardial infarction. *J Am Coll Cardiol* 2002; 39:15-21
 43. Schomig A, Kastrati A, Dirschinger J, et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. *N Engl J Med* 2000; 343:385-391.
 44. Brener SJ, Barr LA, Burchenal JE, Wolski KE, Effron MB, Topol EJ. Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial. *Am J Cardiol* 1999; 84:728-730, A8
 45. Montalescot G, Barragan P, Wittenberg O, et al, for the ADMIRAL Investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. *N Engl J Med* 2001; 344:1895-1903.
 46. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. *N Engl J Med* 2002; 346:957-966.
 47. Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. *Circulation* 1998; 98:2695-2701.
 48. Schrieber T, Kaplan BM, Gregory ML. Transluminal extraction atherectomy vs balloon angioplasty in acute ischemic syndromes (TOPIT): hospital outcome and six-month status. *J Am Coll Cardiol* 1997; 29(Suppl A):132A.
 49. Nakagawa Y, Matsuo S, Kimura T, et al. Thrombectomy with AngioJet catheter in native coronary arteries for patients with acute or recent myocardial infarction. *Am J Cardiol* 1999; 83:994-999.
 50. Rosenschein U, Roth A, Rassin T, Basan S, Laniado S, Miller HI. Analysis of coronary ultrasound thrombolysis endpoints in acute myocardial infarction (ACUTE trial). Results of the feasibility phase. *Circulation* 1997; 95:1411-1416.
 51. Cox D, Stuckey T, Low R, et al. Adjunctive thrombectomy combined with stenting for AMI: the EndiCOR X-size AMI registry. *J Am Coll Cardiol* 2001; 39(Suppl A):306A.
 52. Giri S, Kuntz RE, Eisenhauer AC, et al. Effect of baseline thrombus in the SAFER (saphenous Vein Graft Angioplasty Free of Emboli Randomized) trial. *J Am Coll Cardiol* 2002; 39 (Suppl A):52A.
 53. Brodie BR, Stuckey TD. Mechanical reperfusion therapy for acute myocardial infarction: Stent PAMI, ADMIRAL, CADILLAC and beyond. *Heart* 2002; 87:191-192.
 54. Kalaria VG, Chaudhary I, Jacobson S, et al. Evolution in the practice of primary angioplasty: effect of adjunctive coronary stenting and glycoprotein IIb/IIIa inhibitors on long-term outcomes. *Catheter Cardiovasc Interv* 2000; 54:327-332.
 55. Stone GW, Peterson MA, Lansky AJ, Dangas G, Mehran R, Leon MB. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. *J Am Coll*

- Cardiol* 2002; 39:591-597.
56. Kaul S. Coronary angiography cannot be used to assess myocardial perfusion in patients undergoing reperfusion for acute myocardial infarction. *Heart* 2001; 86:483-484.
 57. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. *J Clin Invest* 1974; 54:1496-14508.
 58. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Neumann FJ, Chiariello M. Adjunctive mechanical devices to prevent distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction: a meta-analysis of randomized trials. *Am Heart J* 2007; 153:343-353.
 59. Cohen DJ, Taira DA, Berezin R, et al. Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the stent primary angioplasty in myocardial infarction (stent-PAMI) trial. *Circulation* 2001; 104:3039-3045.
 60. Lieu TA, Gurley RJ, Lundstrom RJ, et al. Projected cost-effectiveness of primary angioplasty for acute myocardial infarction. *J Am Coll Cardiol* 199; 30:1741-1750.
 61. Stone GW, Grines CL, Rothbaum D, et al. Analysis of the relative costs and effectiveness of primary angioplasty versus tissue-type plasminogen activator: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. The PAMI Trial Investigators. *J Am Coll Cardiol* 1997; 29:901-907.
 62. Grines CL, Marsalese DL, Brodie B, et al. Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. PAMI-II Investigators. Primary Angioplasty in Myocardial Infarction. *J Am Coll Cardiol* 1998; 31:967-972
 63. Thiemann DR, Coresh J, Schulman SP, Gerstenblith G, Powe NR. Thrombolytic therapy and mortality. *Lancet* 2001; 357:1367-1368.
 64. Thiemann DR, Coresh J, Schulman SP, Gerstenblith G, Oetgen WJ, Powe NR. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. *Circulation* 2000; 101:2239-2246.
 65. DeGeare VS, Stone GW, Grines L, et al. Angiographic and clinical characteristics associated with increased in-hospital mortality in elderly patients with acute myocardial infarction undergoing percutaneous intervention (a pooled analysis of the primary angioplasty in myocardial infarction trials). *Am J Cardiol* 2000; 86:30-34.
 66. Singh M, Mathew V, Garratt KN, et al. Effect of age on the outcome of angioplasty for acute myocardial infarction among patients treated at the Mayo Clinic. *Am J Med* 2000; 108:187-192
 67. Bates ER, Topol EJ. Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock. *J Am Coll Cardiol* 1991; 18:1077-1084.
 68. Grines CL, Booth DC, Nissen SE, et al. Mechanism of acute myocardial infarction in patients with prior coronary artery bypass grafting and therapeutic implications. *Am J Cardiol* 1990; 65:1292-1296.
 69. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. *N Engl J Med* 1999; 341:625-634.
 70. Al Suwaidi J, Velianou JL, Berger PB, et al. Primary percutaneous coronary interventions in patients with acute myocardial infarction and prior coronary artery bypass grafting. *Am Heart J* 2001; 142:452-459.
 71. Urban P, Stauffer JC, Bleed D, et al. A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock-(S)MASH. *Eur Heart J* 1999; 20:1030-1038.
 72. Ammann P, Straumann E, Naegeli B, et al. Long-term results after acute percutaneous transluminal coronary angioplasty in acute myocardial infarction and cardiogenic shock. *Int J Cardiol* 2002; 82:127-131.
 73. Llevadot J, Giugliano RP, McCabe CH, Cannon CP, Antman EM, Murphy S, Gibson CM. Degree of residual stenosis in the culprit coronary artery after thrombolytic administration (Thrombolysis In Myocardial Infarction [TIMI] trials). *Am J Cardiol* 2000; 85:1409-1413.
 74. Simoons ML, Arnold AER, Betriu A, et al. Thrombolysis with t-PA in acute myocardial infarction: no beneficial effects of immediate PTCA. *Lancet* 1988; 1:197-203.
 75. SWIFT trial of delayed elective intervention v conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. SWIFT (Should We Intervene Following Thrombolysis?) Trial Study Group. *Br Med J* 1991; 302:555-560.
 76. Michels KB, Yusuf S. Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials. *Circulation* 1995; 91:476-485.
 77. Gibson CM, Cannon CP, Greene RM, et al. Rescue angioplasty in the thrombolysis in myocardial infarction (TIMI) 4 trial. *Am J Cardiol* 1997; 80:21-26.
 78. Ellis SG, Da Silva ER, Spaulding CM, Nobuyoshi M, Weiner B, Talley JD. Review of immediate angioplasty after fibrinolytic therapy for acute myocardial infarction: insights from the RESCUE I, RESCUE II, and other contemporary clinical experiences. *Am Heart J* 2000; 139:1046-1053.
 79. Schweiger MJ, Cannon CP, Murphy SA, et al for the TIMI 10B and TIMI 14 Investigators. Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). *Am J Cardiol* 2001; 88:831-836.
 80. Bar F, Vainer J, Steinhagen J, et al. Ten-year experience with early angioplasty in 759 patients with acute myocardial infarction. *J Am Coll Cardiol* 2000; 36:51-58.
 81. Ross AM, Lundergan CF, Rohrbeck SC, et al. Rescue angioplasty after failed thrombolysis: technical and clinical outcomes in a large thrombolysis trial. GUSTO-1 Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. *J Am Coll Cardiol* 1998; 31:1511-1517.

82. Miller JM, Smalling R, Ohman EM, et al. Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries. *Am J Cardiol* 1999; 84:779-784.
83. Outcome of attempted rescue coronary angioplasty after failed thrombolysis for acute myocardial infarction. The CORAMI Study Group. Cohort of Rescue Angioplasty in Myocardial Infarction. *Am J Cardiol* 1994; 74:172-174.
84. Ross AM, Coyne KS, Reiner JS, et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial. *J Am Coll Cardiol* 1999; 34:1954-1962.
85. Brodie BR, Stuckey TD, Hansen C, Muncy D. Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction. *Am J Cardiol* 2000 Jan 1; 85(1):13-18.
86. Topol EJ for The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. *Lancet* 2001; 357:1905-1914.
87. Herrmann HC, Moliterno DJ, Ohman EM, et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. *J Am Coll Cardiol* 2000; 36:1489-1496.
88. Gibson CM. A union in reperfusion: the concept of facilitated percutaneous coronary intervention. *J Am Coll Cardiol* 2000; 36:1497-1499.
89. Gibson CM. Primary angioplasty versus thrombolysis: new issues in the era of glycoprotein IIb/IIIa inhibition and intracoronary stenting. *Ann Intern Med* 1999; 130:841-847.
90. Zhu MM, Feit A, Chadow H, Alam M, Kwan T, Clark LT. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials. *Am J Cardiol* 2001; 88:297-301.
91. Kastrati A, Mehilli J, Dirschinger J, et al. Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. *Lancet* 2002;359:920-925.
92. Gibson CM, de Lemos JA, Murphy SA, et. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. *Circulation* 2001; 103:2550-2554.
93. de Lemos JA, Gibson CM, Antman EM, et al, for the TIMI 14 Investigators. Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial. *Am Heart J* 2001; 141:592-598.
94. Le May MR, Wells GA, Labinaz M, et al. Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). *J Am Coll Cardiol* 2005; 46:417-424.
95. Dalby M, Bouzamondo A, Lechat P, Montalescot G. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis. *Circulation* 2003; 108:1809-1814.
96. Wharton TP Jr, Grines LL, Turco MA, et al. Primary angioplasty in acute myocardial infarction at hospitals with no surgery on-site (the PAMI-No SOS study) versus transfer to surgical centers for primary angioplasty. *J Am Coll Cardiol* 2004; 43:1943-1950.
97. Berger JS, Fridman V, Brown DL. Comparison of outcomes in acute myocardial infarction treated with coronary angioplasty alone versus coronary stent implantation. *Am J Cardiol* 2006; 97:977-980.
98. Schömig A, Ndrepepa G, Mehilli J, et al; STOPAMI-4 study investigators. A randomized trial of coronary stenting versus balloon angioplasty as a rescue intervention after failed thrombolysis in patients with acute myocardial infarction. *J Am Coll Cardiol* 2004; 44:2073-2079.
99. Stuckey TD, Stone GW, Cox DA, et al; CADILLAC investigators. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). *Am J Cardiol* 2005; 95:1-7.
100. Applegate RJ, Sacrinty MT, Kutcher MA, et al. Comparison of drug-eluting versus bare metal stents on later frequency of acute myocardial infarction and death. *Am J Cardiol* 2007; 99:333-338.